Manhattan Research Releases Digital DTC Relevance Rankings

Manhattan ResearchMore than 60% of U.S. adults turn to the Internet as a decision support tool in healthcare and disease management, and certain condition groups are more likely to use online health resources than others, according to pharmaceutical and healthcare market research company Manhattan Research. Acne, restless leg syndrome, and cancer patients are among the top ten therapeutic categories adopting eHealth activities, which can range from reading a health-related blog to joining an online patient community. The increasing use of consumer reliance on the Internet for health and pharmaceutical information is transforming digital direct-to-consumer (DTC) marketing from a "nice to have" tactic to an essential communication channel for pharma companies reaching consumer audiences.

Manhattan Research releases its Digital DTC Relevance Rankings, revealing which condition groups are most likely to use the Internet for health information out of a pool of over 100 therapeutic categories. The findings come from Cybercitizen Health™ v8.0, the company's consumer market research and advisory service. The Digital DTC Relevance chart shows that for some brands, such as those targeting acne, adult ADHD, and fibromyalgia patients, it's especially critical to take note of digital opportunities in shaping future DTC marketing strategies.

Digital DTC Relevance Rankings
Top Condition Groups Online for Health

Ranked by number of U.S. adults

1. Acne
2. Adult ADHD (Attention Deficit Hyperactivity Disorder)
3. Fibromyalgia
4. Migraine
5. Allergies
6. Irritable Bowel Syndrome
7. Anxiety Disorder/Social Phobia
8. Asthma
9. Restless Leg Syndrome
10. Cancer

Among U.S. adults (18+)
Source: Cybercitizen Health™ v8.0 (2008)

"This is the year in which pharmaceutical companies must stop merely 'talking at' consumers and begin communicating with them. The old way of DTC marketing isn’t going to cut it as the consumer media landscape evolves," said Meredith Abreu Ressi, Vice President of Research at Manhattan Research. "Though we've shared just a few of the top condition groups online for health, the reality is that all pharmaceutical marketers are finding that their target audiences are shifting from traditional offline sources to the Internet for their everyday needs, including health management."

Manhattan Research at the DTC National Conference
Manhattan Research Vice President of Research Meredith Abreu Ressi will be presenting "How New Media Changes Pharmaceutical DTC Advertising" with Jeff Hitchcock, President and Founder of Children with Diabetes, a Johnson and Johnson Company, at the DTC National Conference on Thursday, April 16, 2009 in Washington D.C.

For more information about the DTC National Conference, please visit: http://www.dtcperspectives.com/website/Conferences/DTC-National/DTC-National-Main.html

Request a Complimentary Overview of Digital Trends for Your Therapeutic Audience
Manhattan Research offers complimentary overviews of how over 100 consumer therapeutic groups use the Internet and other technology for healthcare. This one-page snapshot is a preview of Manhattan Research's Therapeutic Segmentation Modules, which are comprehensive analyses of specific patient markets based on the Cybercitizen Health™ and ePharma Consumer® studies. To request an overview of digital trends for your therapeutic audience, please visit http://www.manhattanresearch.com/products/Therapeutic_Segmentations/therapeutic-segmentation-overview-request.aspx

For a list of available consumer therapeutic segmentation modules and topics, please visit http://www.manhattanresearch.com/products/Therapeutic_Segmentations

For a list of available physician specialist segmentation modules and topics, please visit http://www.manhattanresearch.com/products/Specialist_Segmentations

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Europe, Taking the Pulse® Asia, Cybercitizen Health™, Cybercitizen Health™ Europe, ePharma Consumer®, and ePharma Physician®. Broad consumer and physician research is complemented by targeted analysis among more than 100 consumer therapeutic egments and 25 physician specialist segments. For information, please visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.decisionresourcesinc.com.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...